303 related articles for article (PubMed ID: 24275667)
21. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
Chowdary P
Drugs; 2018 Jun; 78(9):881-890. PubMed ID: 29845491
[TBL] [Abstract][Full Text] [Related]
22. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor.
Iakhiaev A; Ruf W; Rao LV
Thromb Haemost; 2001 Mar; 85(3):458-63. PubMed ID: 11307815
[TBL] [Abstract][Full Text] [Related]
23. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
Hoffman M; Monroe DM
Dis Mon; 2003 Jan; 49(1):14-21. PubMed ID: 12525825
[TBL] [Abstract][Full Text] [Related]
24. Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy.
Mast AE; Ruf W
J Thromb Haemost; 2022 Jun; 20(6):1290-1300. PubMed ID: 35279938
[TBL] [Abstract][Full Text] [Related]
25. A computer modeling study of the interaction between tissue factor pathway inhibitor and blood coagulation factor Xa.
Yoneda T; Komooka H; Umeyama H
J Protein Chem; 1997 Aug; 16(6):597-605. PubMed ID: 9263122
[TBL] [Abstract][Full Text] [Related]
26. Tissue factor-independent inhibition of thrombin generation by tissue factor pathway inhibitor-α.
Thomassen MC; Heinzmann AC; Herfs L; Hartmann R; Dockal M; Scheiflinger F; Hackeng TM; Rosing J
J Thromb Haemost; 2015 Jan; 13(1):92-100. PubMed ID: 25348176
[TBL] [Abstract][Full Text] [Related]
27. Potential role of activated factor VIII (FVIIIa) in FVIIa/tissue factor-dependent FXa generation in initiation phase of blood coagulation.
Furukawa S; Nogami K; Ogiwara K; Shima M
Int J Hematol; 2019 Apr; 109(4):390-401. PubMed ID: 30756344
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces.
Hamamoto T; Yamamoto M; Nordfang O; Petersen JG; Foster DC; Kisiel W
J Biol Chem; 1993 Apr; 268(12):8704-10. PubMed ID: 8473315
[TBL] [Abstract][Full Text] [Related]
29. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
Hoffman M; Monroe DM
Semin Hematol; 2001 Oct; 38(4 Suppl 12):6-9. PubMed ID: 11735103
[TBL] [Abstract][Full Text] [Related]
30. The effect of leukocyte elastase on tissue factor pathway inhibitor.
Higuchi DA; Wun TC; Likert KM; Broze GJ
Blood; 1992 Apr; 79(7):1712-9. PubMed ID: 1558967
[TBL] [Abstract][Full Text] [Related]
31. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
Waters EK; Genga RM; Schwartz MC; Nelson JA; Schaub RG; Olson KA; Kurz JC; McGinness KE
Blood; 2011 May; 117(20):5514-22. PubMed ID: 21389323
[TBL] [Abstract][Full Text] [Related]
32. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway.
Sevinsky JR; Rao LV; Ruf W
J Cell Biol; 1996 Apr; 133(2):293-304. PubMed ID: 8609163
[TBL] [Abstract][Full Text] [Related]
33. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor.
van 't Veer C; Hackeng TM; Delahaye C; Sixma JJ; Bouma BN
Blood; 1994 Aug; 84(4):1132-42. PubMed ID: 8049429
[TBL] [Abstract][Full Text] [Related]
34. Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.
Santamaria S; Reglińska-Matveyev N; Gierula M; Camire RM; Crawley JTB; Lane DA; Ahnström J
J Biol Chem; 2017 Jun; 292(22):9335-9344. PubMed ID: 28420729
[TBL] [Abstract][Full Text] [Related]
35. Tissue factor pathway.
McVey JH
Baillieres Best Pract Res Clin Haematol; 1999 Sep; 12(3):361-72. PubMed ID: 10856975
[TBL] [Abstract][Full Text] [Related]
36. Lipid-bound factor Xa regulates tissue factor activity.
Hathcock J; Rusinova E; Vaananen H; Nemerson Y
Biochemistry; 2007 May; 46(20):6134-40. PubMed ID: 17469850
[TBL] [Abstract][Full Text] [Related]
37. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat.
Han X; Girard TJ; Baum P; Abendschein DR; Broze GJ
Arterioscler Thromb Vasc Biol; 1999 Oct; 19(10):2563-7. PubMed ID: 10521388
[TBL] [Abstract][Full Text] [Related]
38. Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia.
Chowdary P
Int J Hematol; 2020 Jan; 111(1):42-50. PubMed ID: 30302740
[TBL] [Abstract][Full Text] [Related]
39. An all-atom solution-equilibrated model for human extrinsic blood coagulation complex (sTF-VIIa-Xa): a protein-protein docking and molecular dynamics refinement study.
Venkateswarlu D; Duke RE; Perera L; Darden TA; Pedersen LG
J Thromb Haemost; 2003 Dec; 1(12):2577-88. PubMed ID: 14750502
[TBL] [Abstract][Full Text] [Related]
40. Role of exosite binding modulators in the inhibition of Fxa by TFPI.
Peraramelli S; Thomassen S; Heinzmann A; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M; Rosing J
Thromb Haemost; 2016 Mar; 115(3):580-90. PubMed ID: 26607136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]